NIMRAD - A Phase III trial to investigate the use of Nimorazole hypoxia modification with Intensity-modulated radiotherapy in head and neck cancer.
Affiliation
Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2014-03-27
Metadata
Show full item recordCitation
NIMRAD - A phase III trial to investigate the use of Nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. 2014: Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2014.03.003PubMed ID
24685344Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2014.03.003
Scopus Count
Collections
Related articles
- Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
- Authors: Thomson DJ, Slevin NJ, Baines H, Betts G, Bolton S, Evans M, Garcez K, Irlam J, Lee L, Melillo N, Mistry H, More E, Nutting C, Price JM, Schipani S, Sen M, Yang H, West CM, NIMRAD Trial Group
- Issue date: 2024 Jul 1
- Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
- Authors: Schnoell J, Stanisz I, Jank BJ, Stanek V, Schmid R, Brunner M, Heiduschka G, Kotowski U
- Issue date: 2022 Apr
- DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
- Authors: Overgaard J, Hoff CM, Hansen HS, Specht L, Overgaard M, Lassen P, Andersen E, Johansen J, Andersen LJ, Evensen JF, Alsner J, Grau C
- Issue date: 2018 Apr
- INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA.
- Authors: Mitryayeva N, Grebinyk L, Artiukh S, Bilozor N, Starenkiy V
- Issue date: 2024 Dec 19
- Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
- Authors: Metwally MA, Frederiksen KD, Overgaard J
- Issue date: 2014 May